STADOL
LOE ApproachingNDANASALSPRAY, METERED
Approved
Dec 1991
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 16h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
STADOL is a nasal metered spray formulation approved in 1991 by Bristol Myers Squibb. The specific indication and mechanism of action are not disclosed in available data, but the nasal route suggests rapid-onset systemic delivery. This is a small-molecule product in the mature/late stage of its commercial lifecycle.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30); brand teams should prepare for generic erosion and transition strategy execution.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings reflect the mature, late-stage status of STADOL. Career opportunities are concentrated in defensive brand management, generic transition planning, and legacy product optimization rather than growth or innovation roles. This assignment suits professionals with expertise in market consolidation and cost-containment strategies.
Brand ManagerField Sales Representative
Worked on STADOL at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.